Premium – Page 2 – Endpoints News

SUBSCRIBE

Biotechs are spending record sums on R&D — should that worry you at least a little?

5 months ago

A microcap biotech salves old wounds with positive PhII report on status epilepticus, but plenty of questions remain

5 months ago

Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?

5 months ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

5 months ago

Webinar: Real World Endpoints — the brave new world coming in building franchise therapies

6 months ago

Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts

6 months ago

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

6 months ago

What makes Hal Barron tick? Look at the people he’s teaming up with at GSK

7 months ago

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization

7 months ago

H1 analysis: The high-stakes table in the biotech deals casino is paying out some record-setting winnings

7 months ago

The top 15 mega-deals in biopharma: AbbVie and Bristol-Myers acquisitions stir fresh debate over what's too big to buy

8 months ago

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

8 months ago

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 offensive

9 months ago

The top 50 biotechs by market cap — and what their CEOs’ compensation deals tell us about biopharma

9 months ago

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

9 months ago

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to China?

10 months ago

Going gangbusters: The top 20 biotech platform deals by upfront cash

10 months ago

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

10 months ago

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

10 months ago

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

11 months ago

The top 10 Alzheimer's deals tell us a lot about a big change of direction for a disaster-prone field

11 months ago

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

11 months ago

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

12 months ago

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

Last year

First page Previous page 123 4 Next page Last page